{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T14:27:48Z","timestamp":1780756068241,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Cancer Center Research and Development Funds","award":["20S-3"],"award-info":[{"award-number":["20S-3"]}]},{"name":"the National Cancer Center Research and Development Funds","award":["23-A-16"],"award-info":[{"award-number":["23-A-16"]}]},{"name":"the National Cancer Center Research and Development Funds","award":["23-A-19"],"award-info":[{"award-number":["23-A-19"]}]},{"name":"the National Cancer Center Research and Development Funds","award":["26-A-4"],"award-info":[{"award-number":["26-A-4"]}]},{"name":"the National Cancer Center Research and Development Funds","award":["29-A-3"],"award-info":[{"award-number":["29-A-3"]}]},{"name":"the National Cancer Center Research and Development Funds","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"crossref","award":["JP16ck0106048"],"award-info":[{"award-number":["JP16ck0106048"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The blood concentration of S-1 and adverse events are affected by renal function. Herein, an S-1 dosage formula was developed based on renal function, indicating the dose for a target blood concentration. This study aimed to explore the usefulness of the formula in adjuvant chemotherapy for gastric cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this ad hoc analysis of the JCOG1001 trial, which evaluated the role of bursectomy for resectable gastric cancer, the recommended dose of S-1 was calculated using the following formula: 1447.8\u00a0\u00d7\u00a0(14.5\u2009+\u20090.301\u00a0\u00d7\u00a0CLcr\u2009+\u20098.23\u00a0\u00d7\u00a0SEX [male\u2009=\u20091, female\u2009=\u20090])\u00a0\u00d7\u00a0body surface area (BSA) (mg\/day). Patients were divided into three groups by comparing the initial S-1 dose determined using BSA with the dose recommended by the formula: underdose (UD), equal dose (ED), and overdose (OD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 686 eligible patients, 58, 304, and 324 patients were classified into the UD, ED, and OD groups. The patients\u2019 characteristics in the UD\/ED\/OD groups were median age (53.5\/64.0\/67.5\u00a0years), male sex (98.3%\/75.3%\/58.0%), and median BMI (24.8\/22.8\/22.3), respectively. The planned 1-year adjuvant S-1 therapy was completed in 74.1%\/73.7%\/68.5%, dose reduction was required in 8.6%\/21.1%\/30.6%, and treatment schedule was altered in 8.6%\/17.1\/19.8% in the UD\/ED\/OD groups, resulting in the 5-year overall survival rates of 77.3%\/74.3%\/77.0%, respectively. The incidences of grade\u2009&gt;\u20093 anemia, thrombocytopenia, diarrhea, stomatitis, and anorexia were significantly higher in the OD group than in the ED and UD groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Dose optimization using an S-1 dosage formula can potentially reduce grade\u2009\u2265\u20093 adverse events for overdosed patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10120-022-01315-8","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T07:07:04Z","timestamp":1656486424000},"page":"1073-1081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001)"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-9516","authenticated-orcid":false,"given":"Takeshi","family":"Kawakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Mizusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Imazeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"1315_CR1","unstructured":"Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. https:\/\/gco.iarc.fr\/today, Accessed 30 Mar 2022."},{"key":"1315_CR2","unstructured":"Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan (Vital Statistics of Japan). https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/summary.html, Accessed 30 Mar 2022."},{"key":"1315_CR3","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810\u201320.","journal-title":"N Engl J Med"},{"key":"1315_CR4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","volume":"37","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: Interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296\u2013304.","journal-title":"J Clin Oncol"},{"key":"1315_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.2017.35.4_suppl.193","volume":"35","author":"T Kawakami","year":"2017","unstructured":"Kawakami T, Machida N, Shirasu H, Yamazaki K, Terashima M, Yasui H, et al. The impact of dose modification or termination of S-1 as adjuvant therapy on survival of locally advanced gastric cancer underwent curative gastrectomy. J Clin Oncol. 2017;35:193.","journal-title":"J Clin Oncol"},{"key":"1315_CR6","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s10120-017-0767-9","volume":"21","author":"K Fujitani","year":"2018","unstructured":"Fujitani K, Kurokawa Y, Takeno A, Endoh S, Ohmori T, Fujita J, et al. Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer? Gastric Cancer. 2018;21:446\u201352.","journal-title":"Gastric Cancer"},{"key":"1315_CR7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3892\/ol.2012.882","volume":"4","author":"H Tsujimoto","year":"2012","unstructured":"Tsujimoto H, Horiguchi H, Hiraki S, Yaguchi Y, Takahata R, Kumano I, et al. Tolerability of adjuvant chemotherapy with S-1 after curative resection in patients with stage II\/III gastric cancer. Oncol Lett. 2012;4:1135\u20139.","journal-title":"Oncol Lett"},{"key":"1315_CR8","first-page":"4004","volume":"53","author":"T Shirasaka","year":"1993","unstructured":"Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53:4004\u20139.","journal-title":"Cancer Res"},{"key":"1315_CR9","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548\u201357.","journal-title":"Anticancer Drugs"},{"key":"1315_CR10","first-page":"2602","volume":"56","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996;56:2602\u20136.","journal-title":"Cancer Res"},{"key":"1315_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cas.12044","volume":"104","author":"SJ Kim","year":"2013","unstructured":"Kim SJ, Kim YJ, Kim JH, Park DJ, Kim HH, Lee JS, et al. Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer. Cancer Sci. 2013;104:116\u201323.","journal-title":"Cancer Sci"},{"key":"1315_CR12","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1245\/s10434-017-5923-2","volume":"24","author":"K Yamashita","year":"2017","unstructured":"Yamashita K, Kurokawa Y, Yamamoto K, Hirota M, Kawabata R, Mikami J, et al. Risk factors for poor compliance with adjuvant S-1 chemotherapy for gastric cancer: a multicenter retrospective study. Ann Surg Oncol. 2017;24:2639\u201345.","journal-title":"Ann Surg Oncol"},{"key":"1315_CR13","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s10120-015-0536-6","volume":"19","author":"E Booka","year":"2016","unstructured":"Booka E, Imamura CK, Takeuchi H, Hamamoto Y, Gomi D, Mizukami T, et al. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study. Gastric Cancer. 2016;19:876\u201386.","journal-title":"Gastric Cancer"},{"key":"1315_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/cas.14758","volume":"112","author":"M Takeuchi","year":"2021","unstructured":"Takeuchi M, Imamura CK, Booka E, Takeuchi H, Mizukami T, Kawakami T, et al. Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application. Cancer Sci. 2021;112:751\u20139.","journal-title":"Cancer Sci"},{"key":"1315_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S2468-1253(18)30090-6","volume":"3","author":"Y Kurokawa","year":"2018","unstructured":"Kurokawa Y, Doki Y, Mizusawa J, Terashima M, Katai H, Yoshikawa T, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2018;3:460\u20138.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1315_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321.","journal-title":"Lancet Oncol"},{"key":"1315_CR17","doi-asserted-by":"crossref","unstructured":"Booka E, Boku N, Imamura CK, Takeuchi M, Kawakubo H, Takeuchi H, et al. Gastric cancer evaluation of clinical validity of an S-1 dosage formula based on renal function by using data of the SPIRITS and the G-SOX trials. Gastric Cancer. 2022;361 (in press)","DOI":"10.1007\/s10120-022-01291-z"},{"key":"1315_CR18","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s10120-021-01228-y","volume":"24","author":"A Tsuburaya","year":"2021","unstructured":"Tsuburaya A, Guan J, Yoshida K, Kobayashi M, Yoshino S, Tanabe K, et al. Clinical biomarkers in adjuvant chemotherapy for gastric cancer after D2 dissection by a pooled analysis of individual patient data from large randomized controlled trials. Gastric Cancer. 2021;24:1184\u201393.","journal-title":"Gastric Cancer"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-022-01315-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-022-01315-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-022-01315-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T14:26:19Z","timestamp":1666448779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-022-01315-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1315"],"URL":"https:\/\/doi.org\/10.1007\/s10120-022-01315-8","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"16 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takeshi Kawakami received honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, and Bristol-Myers Squibb. Junki Mizusawa received National Cancer Center Research and Development Funds and Japan Agency for Medical Research and Development via his institution and honoraria from Taiho Pharmaceutical and Chugai Pharmaceutical. Satoru Iwasa received research funding from Taiho Pharmaceutical via his institution and honoraria from Taiho Pharmaceutical. Narikazu Boku received grants from Ono Pharmaceutical and Takeda Pharmaceutical, honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Taiho Pharmaceutical, and Daiichi-Sankyo. Yuichiro Doki received honoraria from Taiho Pharmaceutical. Takaki Yoshikawa received lecture fee from Taiho Pharmaceutical. Yukinori Kurokawa received lecture fee from Taiho Pharmaceutical. Masanori Terashima received honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Ono Pharmaceutical, Bristol-Myers Squibb Japan, Yakult Honsha, Takeda Pharmaceutical, Pfizer Japan, Astra-Zeneca, Daiichi-Sankyo, Johnson and Johnson, Medtronic Japan, Intuitive Japan, and Olympus. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}